ArticleBone marrow transplantation2026
GVHD prophylaxis and incidence in contemporary alloHSCT: a large real-world GETH/TC analysis.
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes. The increasing use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) has expanded beyond haploidentical transplantation to matched related (MRD) and unrelated donor (MUD) settings, although real-world GVHD incidence in this context is not well characterized. We performed a nationwide retrospective study including 1544 alloHSCTs conducted in Spain between 2018 and 2020. PTCy-based prophylaxis was used in 65.6% of transplants, being almost universal in haploidentical procedures (96.9%) and predominant in mismatched donors (72.4%), with notable use in MRD (43.5%) and MUD (56.8%). The cumulative incidence of grade II-IV acute GVHD at day +100 and 1 year was 28.4% and 30.7%, respectively, while grade III-IV occurred in 6.9% and 8.0%. Despite the prevalent use of peripheral blood stem cells, chronic GVHD at 2 years was 36.7%, with 23.5% moderate-to-severe. Acute GVHD was strongly associated with inferior survival (HR 2.40; P < 0.001), particularly grade III-IV disease (HR 4.34; P < 0.001). This large nationwide real-world study highlights the shift in GVHD prophylaxis in modern alloHSCT and underscores the need to define new studies based on this evolving landscape.
Identifiers
42754641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.